In the US, Romiplostim (romiplostim systemic) is a member of the drug class platelet-stimulating agents and is used to treat Idiopathic Thrombocytopenic Purpura.
US matches:
- Romiplostim
- Romiplostim Subcutaneous
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
B02BX04
CAS registry number (Chemical Abstracts Service)
0267639-76-9
Chemical Formula
C2634-H4086-N722-O790-S18
Molecular Weight
59085
Therapeutic Categories
Platelet stimulating factor
Thrombopoietin receptor agonist
Chemical Names
L-methionyl [human immunglobulin heavy constant gamma 1-(227 C-terminal residues)-peptide (Fc fragment)] fusion protein with 41 amino acids peptide, (7-7':10,10')-bisdisulfide dimer (WHO)
Methionyl, 227 amino acid C-terminal Immunoglobulin G1 (human Fc fragment) fusion protein with 41 amino acid peptide, dimer (USAN)
Foreign Names
- Romiplostimum (Latin)
- Romiplostim (German)
- Romiplostim (French)
- Romiplostim (Spanish)
Generic Names
- Romiplostim (OS: USAN)
- AMG 531 (IS: Amgen)
Brand Names
- Nplate
Amgen, Australia; Amgen, Canada; Amgen, Germany; Amgen, Spain; Amgen, France; Amgen, United Kingdom; Amgen, Greece; Amgen, Sweden; Amgen, Slovakia; Amgen, United States; Amgen Europe, Austria; Amgen Switzerland, Switzerland
International Drug Name Search
Glossary
IS | Inofficial Synonym |
OS | Official Synonym |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
USAN | United States Adopted Name |
WHO | World Health Organization |
Click for further information on drug naming conventions and
International Nonproprietary Names.